...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International immunopharmacology >Nasal sodium cromoglycate (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: A preliminary study
【24h】

Nasal sodium cromoglycate (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: A preliminary study

机译：鼻碳酸钠（Lomusol）调节轻度至中度持续过敏性鼻炎的早期相位反应，以便单声敏感尘螨患者：初步研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We evaluated the clinical improvement of patients with mild to moderate persistent allergic rhinitis (AR) due to mono-sensitization to house dust mite (HDM) allergen, by sodium cromoglycate nasal spray (Lomusol 4%). Lomusol was used as a single agent treatment, and its anti-inflammatory effects, in the early phase reaction were evaluated. Herein we showed that Lomusol significantly improved the subjective nasal symptom scores especially nasal obstruction. This was associated with significant and specific reduction in neutrophils influx in nasal cytology but had no effect on other cell types. This selective anti-inflammatory effect on nasal cytology was associated with significant reduction in the levels of platelet activating factor (PAF) and histamine in nasal secretions but had no effect on PGD2, LTC4 or CysLt levels. Lomusol was also able to induce significant reduction in eosinophil cationic protein (ECP) levels in nasal secretions without altering the percentage of eosinophil influx in nasal cytology. Taken collectively, we showed the first evidence that nasal sodium cromoglycate possesses a selective inhibition on neutrophil recruitment into nasal cytology in the early phase reaction of AR patients mono-sensitized to HDM. This may be attributed to the ability of Lomusol to significantly reduce the amount of PAF recovered in nasal secretion. These results were associated with significant improvement in subjective symptom scores especially nasal obstruction that may in addition, be due to the ability of Lomusol to down-regulate eosinophil degranulation activity as well. (c) 2015 Elsevier B.V. All rights reserved.
机译：我们评估了轻度到中度持续过敏性鼻炎（AR）患者的临床改善，因为单次敏化粉末过敏原，通过甘甘露糖苷鼻腔喷雾（Lomusol 4％）。利用Lomusol作为单一剂处理，并评估早期反应中的抗炎作用。在此，我们表明，Lomusol显着改善了主观鼻症状评分特别是鼻塞。这与鼻细胞学中的中性粒细胞流入的显着和特异性降低有关，但对其他细胞类型没有影响。这种对鼻细胞学的选择性抗炎作用与血小板激活因子（PAF）和组胺在鼻中分泌物的显着降低有关，但对PGD2，LTC4或CySLT水平没有影响。 Lomusol还能够在鼻中分泌物中诱导嗜酸性粒细胞阳离子蛋白（ECP）水平的显着降低，而不会改变鼻细胞学中嗜酸性粒细胞中流量的百分比。我们举起了第一种证据表明，第一种证据表明鼻碳酸钠对中性粒细胞募集到鼻细胞学中的鼻细胞学中的AR患者单对HDM的早期反应中的选择性抑制。这可能归因于Lomusol显着减少在鼻分泌中恢复的PAF量的能力。这些结果与主观症状评分的显着改善有关，特别是鼻塞可能是由于Lomusol的能力，也是下调嗜酸性粒细胞脱粒活性。 （c）2015 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号